<DOC>
	<DOCNO>NCT00792103</DOCNO>
	<brief_summary>The primary objective evaluate safety long-term treatment NP101 assess : - Subject self-examination skin irritation score - Adverse event - Changes vital sign ECG parameters The secondary objective evaluate long term efficacy NP101 assess : - Headache pain free two hour patch activation initial acute migraine attack treat NP101 - Headache pain relief two hour patch activation initial acute migraine attack treat NP101 - Nausea free two hour patch activation initial acute migraine attack treat NP101 - Phonophobia free two hour patch activation initial acute migraine attack treat NP101 - Photophobia free two hour patch activation initial acute migraine attack treat NP101 - Migraine free two hour patch activation initial acute migraine attack treat NP101 This study use open-label design ass long term safety NP101 ( sumatriptan iontophoretic transdermal patch ) . Subjects continue good health ( use triptan use NP101 patch contraindicate ) receive treatment ( patch activation ) study patch qualify migraine study NP101-007 consider eligible enrollment open-label study . Subjects expect remain study 12 month .</brief_summary>
	<brief_title>An Open-Label Study Evaluate Safety NP101 Treatment Acute Migraine Over 12 Months</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subject previously enrol study NP101007 treat ( patch activation ) qualify migraine . Subject judge good health , base upon result medical history , physical examination , vital sign , ECG . Subjects clinically significant abnormal vital sign ECG parameter order qualify enrollment . ECG must do enrollment NP101008 unless ECG Final Visit study NP101007 conduct within 30 day . Female subject childbearing potential ( surgically sterile 2 year post menopausal ) must negative pregnancy test enrollment . Subject less two potential skin application site . Subject clinically significant abnormal vital sign ECG parameter adverse event participate NP101007 would preclude continued treatment NP101 patch . Subject change medical history medication use would preclude use sumatriptan per approve ImitrexÂ® product Prescribing Information ( PI ) safe use NP101 per NP101 Investigator 's Brochure . Subject plan start , stop , change treatment dose follow within 3 month prior subject 's study Enrollment date Final Visit : anxiolytic , lithium mood stabilizer valproate , carbamazepine lamotrigine , hypnotic antipsychotic . Subject take nontriptan serotonergic drug include selective serotonin reuptake inhibitor ( SSRI ) , serotonin norepinephrine reuptake inhibitor ( SNRI ) , tricyclic antidepressant ( TCAs ) , monoamine oxidase inhibitor ( MAOI ) preparation contain St. John 's Wort within 1 month prior enrollment and/or plan start medication study ( Final Visit ) . Female subject pregnant , breast feeding , childbearing potential , use unwilling use effective form contraception study period 30 day follow Final Visit . Acceptable method contraception include barrier method spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted inject ) abstinence . If exclusive male partner surgically sterile , acceptable . Subject participate clinical study within 30 day enrollment ( exclude NP101007 ) plan participate another clinical study duration NP101008 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>